pharmaphorum May 17, 2024
A report issued by the office of US Senator Bernie Sanders has claimed that the high prices being charged for new GLP-1 agonist-based obesity therapies like Novo Nordisk’s Wegovy could end up bankrupting US healthcare systems.
Staff in the Senate Health, Education, Labor, and Pensions (HELP) committee, which Sanders chairs, estimate that widespread use of Wegovy (semaglutide) and other new weight-loss drugs like Eli Lilly’s Zepbound (tirzepatide) could drive the US prescription medicines bill to around $1 trillion a year.
If just half the eligible people with obesity in the US received the drugs, it could cost $411 billion a year – greater than the entire US drugs bill in 2022 – with Medicare/Medicaid alone accounting for $166 billion of...
Today's Sponsors
Today's Sponsor